Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
MEDICAL FRONTIERS - Annual Meeting of the American Society of Hematology
A New Era of Chemotherapy-free Treatments Emerges for Chronic Lymphocytic Leukemia
Atlanta, Georgia / December 9-12, 2017
Atlanta - The recent approvals of many effective, well-tolerated novel agents for chronic lymphocytic leukemia (CLL) have changed the treatment landscape. Researchers are learning how best to sequence and potentially combine novel...
PRIORITY PRESS - 56th Annual Meeting of the American Society of Hematology (ASH)
Selecting Second- and Third-Line TKIs in CML: Offering Tolerability in the Context of Indefinite Disease Control
San Francisco, California / December 6-9, 2014
San Francisco - A focus on the relative long-term safety and tolerability of available tyrosine kinase inhibitors (TKIs) for treatment of chronic myeloid leukemia (CML) has been intensified by the evidence that drugs in this class, when...
PRIORITY PRESS - 7th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
New Treatment Strategies for Prophylaxis in Severe Hemophilia: Moving from Clinical Trials into Real World Practice
Brussels, Belgium / February 26-28, 2014
Brussels - The focus of care in hemophilia A and B has shifted from the management of acute bleeding episodes (on-demand therapy) toward prophylaxis to prevent bleeding episodes and disease sequelae. Currently, hemophilia A patients...
PRIORITY PRESS - 55th Annual Meeting of the American Society of Hematology (ASH)
Strategies for Control of Multiple Myeloma Refined By New and Extended Data Analysis of Major Trials
New Orleans, Louisiana / December 7-10, 2013
New Orleans - Of data with practice-changing implications for control of multiple myeloma presented at ASH 2013, the most significant involved dosing of front-line therapy in those who are transplant-ineligible. In this group, it was shown...
PRIORITY PRESS - XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH)/ 59th Annual Scientific and Standardization Committee (SSC) Meeting
Potential for Advances in the Treatment of Hemophilia A
Amsterdam, The Netherlands / June 29-July 4, 2013
Amsterdam - Current treatment for patients with hemophilia A, the most common hereditary coagulation disorder, involves intravenous injection of human factor VIII given on demand in response to a bleeding event or as a prophylactic therapy....
MEDICAL FRONTIERS - XXIV Congress of the International Society of Thrombosis and Haemostasis (ISTH)/ 59th Annual SSC Meeting
New Horizons in the Treatment of Hemophilia A and B
Amsterdam, The Netherlands / June 29–July 4, 2013
Amsterdam - Current treatment for patients with hemophilia involves intravenous injection of clotting factor concentrate either given on demand in response to a bleeding event or as prophylactic therapy. Since the introduction of...
PRIORITY PRESS - Annual General Meeting of the Canadian Society of Nephrology
New Insights in the Treatment of Atypical Hemolytic Uremic Syndrome
Montreal, Quebec / April 24-28, 2013
Montreal - Atypical hemolytic uremic syndrome (aHUS) is a rare condition caused by a genetic or acquired deficiency in the complement system. Its features include progressive and potentially fatal involvement of the kidneys and circulatory...
PRIORITY PRESS - 54th Annual Meeting of the American Society of Hematology
Improving Outcomes in Disorders of Complement Activation
Atlanta, Georgia / December 8-11, 2012
Atlanta - Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are chronic, life-threatening hematologic conditions that have limited therapeutic options. Both conditions arise from uncontrolled complement...
PRIORITY PRESS - 54th Annual Meeting of the American Society of Hematology
Seeking Better Outcomes for Indolent Lymphomas
Atlanta, Georgia / December 8-11, 2012
Atlanta - Decades of laboratory and clinical research have yet to determine the optimal therapy for indolent non-Hodgkin lymphoma and mantle-cell lymphoma. The combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)...